Brigit Biofarmaka Teknologi Tbk. vs Super Bank Indonesia Tbk. — how do they compare? Brigit Biofarmaka Teknologi Tbk. trades at Rp242 (market cap 164.65B, 187.4K 24h volume), while Super Bank Indonesia Tbk. trades at Rp540 (market cap 19.13T, 68.31M 24h volume). The key difference: Super Bank Indonesia Tbk. is far larger — about 116.2× Brigit Biofarmaka Teknologi Tbk.'s market cap, and Super Bank Indonesia Tbk. is more actively traded (68.31M versus 187.4K). Which is the better fit depends on your goals.
| OBAT | SUPA | |
|---|---|---|
Market Cap | 164.65B | 19.13T |
Volume | 187.4K | 68.31M |
Lot | 1.87K | 683.12K |
Turnover | 44.35M | 37.01B |
Average Price | 236.67 | 541.76 |
Value | 44.35M | 37.01B |
Indicative Equilibrium Price | 242 | 540 |
Indicative Equilibrium Volume | 500 | 11.06K |
Trailing returns across standard periods
Latest headlines on both assets
PT. Brigit Biofarmaka Teknologi Tbk. (the Company) was established based on Notarial Deed No. 103 dated December 14, 2015 of Yoerista Arya Megasari, S.H., M.Kn., Notary in Sukoharjo. The company starts production commercially in 2018.
Read more on OBAT →PT Super Bank Indonesia Tbk. (hereinafter referred to as the Bank) formerly under the name of PT Bank Fama International was established by Deed No. 36 on 5 March 1993, before Notary Herlien, S.H. The Bank has received a license as a commercial bank according to the Decree of the Minister of Finance of the Republic of Indonesia No. 834/KMK.017/1993 dated 11 October 1993.
Read more on SUPA →